Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients

Drug and Alcohol Dependence

Volumn 70, Issue 3, 2003, Pages 315-325

  Kosten, Thomas ^a   Oliveto, Alison ^a   Feingold, Alan ^a   Poling, James ^a   Sevarino, Kevin ^b   McCance Katz, Elinore ^c   Stine, Susan ^d   Gonzalez, Gerardo ^a   Gonsai, Kishor ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Clinical trial; Cocaine dependence; Contingency management; Desipramine; Opiate dependence

Indexed keywords

BUPRENORPHINE; COCAINE; DESIPRAMINE; METHADONE; OPIATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; DRUG URINE LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME; URINE LEVEL; WITHDRAWAL SYNDROME;

EID: 0038752051     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(03)00032-2     Document Type: Article

References (56)

1. Arndt I.O., Dorozynsky L., Woody G.E., McLellan A.T., O'Brien C.P. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch. Gen. Psychiatry. 49:1992;888-893.
2. Ball J.C., Ross A. The Effectiveness of Methadone Maintenance Treatment. 1991;212-232 Springer, New York, NY.
3. Ball J., Corty E., Bond H., Myers C., Tommasello A. The reduction of intravenous heroin use, non-opiate abuse and crime during methadone maintenance treatment: further findings. NIDA Res. Monogr. 81:1988;224-230.
4. Ball J.C., Ross A., Jaffe J.H. Cocaine and heroin use by methadone maintenance patients. NIDA Res. Monogr. 95:1989;328.
5. Bickel W.K., Amass L., Higgins S.T., Badger G.J., Esch R.A. Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J. Consult. Clin. Psychol. 65:1997;803-810.
6. Bigelow G.E., Stitzer M.L., Liebson I.A. The role of behavioral contingency management in drug abuse treatment. NIDA Res. Monogr. 46:1984;36-52.
7. Bryk A.S., Raudenbush S.W. Application of hierarchical linear models to assessing change. Psychol. Bull. 101:1987;147-158.
8. Carroll K.M. Manual-guided psychosocial treatment: a new virtual requirement for pharmacotherapy trials? Arch. Gen. Psychiatry. 54:1997;923-928.
9. Carroll K.M., Nich C., Rounsaville B.J. Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. J. Nerv. Ment. Dis. 183:1995;251-259.
10. Charney D.S., Menkes D.B., Heninger G.R. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch. Gen. Psychiatry. 38:1981;1160-1180.
11. Chutuape M.A., Silverman K., Stitzer M. Contingent reinforcement sustains post-detoxification abstinence from multiple drugs: a preliminary study with methadone patients. Drug Alcohol Depend. 54:1999;69-81.
12. DeMaria P.A. Jr, Sterling R., Weinstein S.P. The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment. Am. J. Addict. 9:2000;145-153.
13. Downey K.K., Helmus T.C., Schuster C.R. Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance. Exp. Clin. Psychopharmacol. 8:2000;176-184.
14. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1995. Structured Clinical Interview for DSM-IV, patient ed. American Psychiatric Press, Washington, DC.
15. Gawin F.H., Kleber H.D., Byck R., Rounsaville B.J., Kosten T.R., Jatlow P.I., Morgan C. Desipramine facilitation of initial cocaine abstinence. Arch. Gen. Psychiatry. 46:1989;117-121.
16. Gibbons R.D., Hedeker D., Elkin I., Waternaux C., Kraemer H.C., Greenhouse J.B., Shea M.T., Imber S.D., Sotsky S.M., Watkins J.T. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch. Gen. Psychiatry. 50:1993;739-750.
17. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L.A., Creson D., Moeller F.G. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 21:2001;522-526.
18. Griffith J.D., Rowan-Szal G.A., Roark R.R., Simpson D.D. Contingency management in outpatient methadone treatment: a meta-analysis. Drug Alcohol Depend. 58:2000;55-66.
19. Hamilton M.A. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
20. Higgins S.T., Delaney D.D., Budney A.J., Bickel W.K., Hughes J.R., Foerg F., Fenwick J.W. A behavioral approach to achieving initial cocaine abstinence. Am. J. Psychiatry. 148:1991;1218-1224.
21. Higgins S.T., Budney A.J., Bickel W.K., Hughes J.R., Foerg F., Badger G. Achieving cocaine abstinence with a behavioral approach. Am. J. Psychiatry. 150:1993;763-769.
22. Higgins S.T., Budney A.J., Bickel W.K., Foerg F.E., Donham R., Badger G.J. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch. Gen. Psychiatry. 51:1994;568-576.
23. Iguchi M.Y., Stitzer M.L., Bigelow G.E., Liebson I.A. Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use. Drug Alcohol Depend. 22:1988;1-7.
24. Johnson R.E., Jaffe J.H., Fudala P.J. A controlled trial of buprenorphine treatment for opioid dependence. J. Am. Med. Assoc. 267:1992;2750-2755.
25. Jones H.E., Haug N., Silverman K., Stitzer M., Svikis D. The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women. Drug Alcohol Depend. 61:2001;297-306.
26. Kosten T.R., Kleber H.D., Morgan C. Treatment of cocaine abuse with buprenorphine. Biol. Psychiatry. 26:1989;637-639.
27. Kosten T.R., Morgan C.M., Falcione J., Schottenfeld R.S. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Arch. Gen. Psychiatry. 49:1992;894-898.
28. Kosten T.R., Rosen M.I., Schottenfeld R.S., Ziedonis D. Buprenorphine for cocaine and opiate dependence. Psychopharmacol. Bull. 28:1992;15-19.
29. Kosten T.R., Rounsaville B.J., Kleber H.D. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped. Arch. Gen. Psychiatry. 44:1987;281-284.
30. Kosten T.R., Schottenfeld R.S., Ziedonis D., Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 181:1993;358-364.
31. Ling W., Wesson D.R., Charuvastra C., Klett C.J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch. Gen. Psychiatry. 53:1996;401-407.
32. Magura S., Casriel C., Goldsmith D.S., Strug D.L., Lipton D.S. Contingency contracting with polydrug-abusing methadone patients. Addict. Behav. 13:1988;113-118.
33. McCaul M.E., Stitzer M.L., Bigelow G.E., Liebson I.A. Contingency management interventions: effects on treatment outcome during methadone detoxification. J. Appl. Behav. Anal. 17:1984;35-43.
34. McLellan A.T., Cacciola J., Kushner H., Peters R., Smith I., Pettinati H. The fifth edition of the addiction severity index: cautions, additions, and normative data. J. Subst. Abuse. 9:1992;461-480.
35. McLellan A.T., Arndt I.O., Metzger D.S., Woody G.E., O'Brien C.P. The effects of psychosocial services in substance abuse treatment. J. Am. Med. Assoc. 269:1993;1953-1959.
36. Milby J.B., Garrett C., English C., Fritschi O., Clarke C. Take-home methadone: contingency effects on drug-seeking and productivity of narcotic addicts. Addict. Behav. 3:1978;215-220.
37. Oliveto A.H., Feingold A., Schottenfeld R., Jatlow P., Kosten T.R. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs. methadone. Arch. Gen. Psychiatry. 56:1999;812-820.
38. Petry N.M., Martin B., Cooney J.L., Kranzler H.R. Give them prizes, and they will come: contingency management for treatment of alcohol dependence. J. Consult. Clin. Psychol. 68:2000;250-257.
39. Preston K.L., Umbricht A., Epstein D.H. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch. Gen. Psychiatry. 57:2000;395-404.
40. Radloff L.S. The CES-D Scale: a self-report depression scale for research in the general population. Appl. Psychol. Measure I. 1977;385-401.
41. Schmitz J.M., Rhoades H.M., Elk R., Creson D., Hussein I., Grabowski J. Medication take-home doses and contingency management. Exp. Clin. Psychopharmacol. 6:1998;162-168.
42. Schottenfeld R.S., Pakes J., Ziedonis D., Kosten T.R. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol. Psychiatry. 34:1993;66-74.
43. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., Kosten T.R. Buprenorphine vs. methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch. Gen. Psychiatry. 54:1997;713-720.
44. Silverman K., Higgins S.T., Brooner R.K., Montoya I.D., Cone E.J., Schuster C.R., Preston K.L. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch. Gen. Psychiatry. 53:1996;409-415.
45. Silverman K., Wong C.J., Umbricht-Schneiter A., Montoya I.D., Schuster C.R., Preston K.L. Broad beneficial effects of cocaine abstinence reinforcement among methadone patients. J. Consult. Clin. Psychol. 66:1998;811-824.
46. Silverman K., Chutuape M.A., Bigelow G.E., Stitzer M.L. Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacologia. 146:1999;128-138.
47. Silverman K., Svikis D., Robles E., Stitzer M.L., Bigelow G.E. A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. Exp. Clin. Psychopharmacol. 9:2001;14-23.
48. Sorensen J.L., Copeland A.L. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 59:2000;17-31.
49. Stitzer M., Bigelow G. Contingency management in a methadone maintenance program: availability of reinforcers. Int. J. Addict. 13:1978;737-746.
50. Stitzer M.L., Bigelow G.E., Liebson I. Reinforcement of drug abstinence: a behavioral approach to drug abuse treatment. NIDA Res. Monogr. 25:1979;68-90.
51. Stitzer M.L., Bigelow G.E., Liebson I.A., Hawthorne J.W. Contingent reinforcement for benzodiazepine-free urines: evaluation of a drug abuse treatment intervention. J. Appl. Behav. Anal. 15:1982;493-503.
52. Stitzer M.L., Iguchi M.Y., Felch L.J. Contingent take-home incentive: effects on drug use of methadone maintenance patients. J. Consult. Clin. Psychol. 60:1992;927-934.
53. Weddington W.W. Jr, Brown B.S., Haertzen C.A., Hess J.M., Mahaffey J.R., Kolar A.F., Jaffe J.H. Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Am. J. Drug Alcohol Abuse. 17:1991;137-152.
54. Woody G.E., Luborsky L., McLellan A.T., O'Brien C.P., Beck A.T., Blaine J., Herman I., Hole A. Psychotherapy for opiate addicts. Does it help. Arch. Gen. Psychiatry. 40:1983;639-645.
55. Woody G.E., McLellan A.T., Luborsky L., O'Brien C.P. Psychotherapy in community methadone programs: a validation study. Am. J. Psychiatry. 152:1995;1302-1308.
56. Zweben J.E., Payte J.T. Methadone maintenance in the treatment of opioid dependence. A current perspective. West. J. Med. 152:1990;588-599.